YAP1-TFE3-fused hemangioendothelioma: a multi-institutional clinicopathologic study of 24 genetically-confirmed cases

YAP1-TFE3- fused hemangioendothelioma is an extremely rare malignant vascular tumor. We present the largest multi-institutional clinicopathologic study of YAP1-TFE3- fused hemangioendothelioma to date. The 24 cases of YAP1-TFE3- fused hemangioendothelioma showed a female predominance (17 female, 7 m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern pathology 2021-12, Vol.34 (12), p.2211-2221
Hauptverfasser:	Dermawan, Josephine K., Azzato, Elizabeth M., Billings, Steven D., Fritchie, Karen J., Aubert, Sebastien, Bahrami, Armita, Barisella, Marta, Baumhoer, Daniel, Blum, Veronika, Bode, Beata, Aesif, Scott W., Bovée, Judith V. M. G., Dickson, Brendan C., van den Hout, Mari, Lucas, David R., Moch, Holger, Oaxaca, Gabriel, Righi, Alberto, Sciot, Raf, Sumathi, Vaiyapuri, Yoshida, Akihiko, Rubin, Brian P.
Format:	Artikel
Sprache:	eng
Schlagworte:	45/91 631/67/1798 692/699/67/1798 Adult Aged Asia Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - analysis Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - genetics Biomarkers, Tumor - analysis Biomarkers, Tumor - genetics Bone tumors CD34 antigen Cytokeratin Cytoplasm Europe Exons Female Gene Fusion Genetic Predisposition to Disease Hemangioendothelioma - chemistry Hemangioendothelioma - genetics Hemangioendothelioma - pathology Hemangioendothelioma - surgery Hemangioendothelioma, Epithelioid - chemistry Hemangioendothelioma, Epithelioid - genetics Hemangioendothelioma, Epithelioid - pathology Hemangioendothelioma, Epithelioid - surgery Humans Laboratory Medicine Leukocytes (eosinophilic) Male Medicine Medicine & Public Health Metastases Middle Aged North America Nucleoli Pathology Patients Phenotype Progression-Free Survival Stroma Time Factors Tumors YAP-Signaling Proteins - genetics Yes-associated protein Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!